Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epidemiology of Parkinson’s disease
Guido Alves, Elin Bjelland Forsaa, Kenn Freddy Pedersen, et al.
Journal of Neurology (2008) Vol. 255, Iss. S5, pp. 18-32
Closed Access | Times Cited: 356

Showing 1-25 of 356 citing articles:

Olfaction in Parkinson's disease and related disorders
Richard L. Doty
Neurobiology of Disease (2011) Vol. 46, Iss. 3, pp. 527-552
Open Access | Times Cited: 397
Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management
João Massano, Kailash P. Bhatia
Cold Spring Harbor Perspectives in Medicine (2012) Vol. 2, Iss. 6, pp. a008870-a008870
Open Access | Times Cited: 388
Parkinson’s disease: The non-motor issues
К. Ray Chaudhuri, Per Odin, Angelo Antonini, et al.
Parkinsonism & Related Disorders (2011) Vol. 17, Iss. 10, pp. 717-723
Closed Access | Times Cited: 370
'The clocks that time us'—circadian rhythms in neurodegenerative disorders
Aleksandar Videnović, Alpár S. Lázár, Roger A. Barker, et al.
Nature Reviews Neurology (2014) Vol. 10, Iss. 12, pp. 683-693
Open Access | Times Cited: 335
Olfactory bulb involvement in neurodegenerative diseases
Johannes Attems, Lauren Walker, K. A. Jellinger
Acta Neuropathologica (2014) Vol. 127, Iss. 4, pp. 459-475
Closed Access | Times Cited: 296
Integration of Clearance Mechanisms: The Proteasome and Autophagy
Esther Wong, Ana María Cuervo
Cold Spring Harbor Perspectives in Biology (2010) Vol. 2, Iss. 12, pp. a006734-a006734
Open Access | Times Cited: 294
The epidemiology of Parkinson's disease
Yoav Ben‐Shlomo, Sirwan K.L. Darweesh, Jorge J. Llibre‐Guerra, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 283-292
Closed Access | Times Cited: 286
Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients
Karlijn J. Doorn, Tim E. Moors, Benjamin Drukarch, et al.
Acta Neuropathologica Communications (2014) Vol. 2, Iss. 1
Open Access | Times Cited: 237
A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia
Gill Livingston, Lynsey Kelly, Elanor Lewis-Holmes, et al.
Health Technology Assessment (2014) Vol. 18, Iss. 39
Open Access | Times Cited: 224
Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected
Antonia Todorova, Peter Jenner, К. Ray Chaudhuri
Practical Neurology (2014) Vol. 14, Iss. 5, pp. 310-322
Open Access | Times Cited: 214
Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease
Aleksandar Videnović, Elizabeth B. Klerman, Wei Wang, et al.
JAMA Neurology (2017) Vol. 74, Iss. 4, pp. 411-411
Open Access | Times Cited: 214
Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
Lígia Fão, Sandra I. Mota, A. Cristina Rego
Ageing Research Reviews (2019) Vol. 54, pp. 100942-100942
Open Access | Times Cited: 214
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Fares Bassil, Pierre‐Olivier Fernagut, Erwan Bézard, et al.
Progress in Neurobiology (2014) Vol. 118, pp. 1-18
Closed Access | Times Cited: 207
Role of metabolism in neurodegenerative disorders
Claudio Procaccini, Marianna Santopaolo, Deriggio Faicchia, et al.
Metabolism (2016) Vol. 65, Iss. 9, pp. 1376-1390
Closed Access | Times Cited: 198
Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson’s disease treatment
Chenchen Bi, Aiping Wang, Yongchao Chu, et al.
International Journal of Nanomedicine (2016) Vol. Volume 11, pp. 6547-6559
Open Access | Times Cited: 168
Multi-modality machine learning predicting Parkinson’s disease
Mary B. Makarious, Hampton L. Leonard, Dan Vitale, et al.
npj Parkinson s Disease (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 85
Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued
Annalisa Pinna
CNS Drugs (2014) Vol. 28, Iss. 5, pp. 455-474
Closed Access | Times Cited: 177
Automatic Classification of Early Parkinson's Disease with Multi-Modal MR Imaging
Dan Long, Jinwei Wang, Min Xuan, et al.
PLoS ONE (2012) Vol. 7, Iss. 11, pp. e47714-e47714
Open Access | Times Cited: 161
Pain in Parkinson disease: A review of the literature
Ayla Fil Balkan, Roberto Cano‐de‐la‐Cuerda, Elena Muñoz-Hellín, et al.
Parkinsonism & Related Disorders (2012) Vol. 19, Iss. 3, pp. 285-294
Open Access | Times Cited: 153
Projected numbers of people with movement disorders in the years 2030 and 2050
Jan‐Philipp Bach, Uta Ziegler, Günther Deuschl, et al.
Movement Disorders (2011) Vol. 26, Iss. 12, pp. 2286-2290
Closed Access | Times Cited: 152
Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)
Elaine Dennison, Juliet Compston, Julie Flahive, et al.
Bone (2012) Vol. 50, Iss. 6, pp. 1288-1293
Open Access | Times Cited: 142
Dietary and lifestyle variables in relation to incidence of Parkinson’s disease in Greece
Andreas Kyrozis, Apostolia Ghika, Panos Stathopoulos, et al.
European Journal of Epidemiology (2013) Vol. 28, Iss. 1, pp. 67-77
Closed Access | Times Cited: 125
Clinical Criteria for the Diagnosis of Parkinson’s Disease
Heinz Reichmann
Neurodegenerative Diseases (2010) Vol. 7, Iss. 5, pp. 284-290
Open Access | Times Cited: 125
MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson’s disease mouse
Zhaohui Wang, Jianlei Zhang, Yan-Li Duan, et al.
Biomedicine & Pharmacotherapy (2015) Vol. 74, pp. 252-256
Closed Access | Times Cited: 104
Glitazone use associated with reduced risk of Parkinson's disease
Brage Brakedal, Irene H. Flønes, Simone Frizell Reiter, et al.
Movement Disorders (2017) Vol. 32, Iss. 11, pp. 1594-1599
Open Access | Times Cited: 98
Page 1 - Next Page

Scroll to top